Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

NCT02283294 is registered in ClinicalTrials.gov with University of South Florida as lead sponsor.

NCT NCT02283294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02283294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Lead sponsor
University of South Florida
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2015
Completion date
June 30, 2019
Enrollment
91 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, stroke, transient ischemic attack